University of California San Francisco

Basu Lab Publications

  1. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    2025 | PubMed
  2. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    2025 | PubMed
  3. The "PRO"mise and "PRO"gress of PROs in cancer clinical trials.
    2024 | PubMed
  4. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    2024 | PubMed
  5. Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients.
    2023 | PubMed
  6. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    2023 | PubMed
  7. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
    2023 | PubMed
  8. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
    2023 | PubMed
  9. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    2022 | PubMed
  10. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    2022 | PubMed
  11. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    2022 | PubMed
  12. ATRX promotes heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress.
    2021 | PubMed
  13. PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.
    2021 | PubMed
  14. Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.
    2021 | PubMed
  15. The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
    2020 | PubMed
  16. Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient Outcomes.
    2020 | PubMed
  17. Call for Data Standardization: Lessons Learned and Recommendations in an Imaging Study.
    2019 | PubMed
  18. RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines.
    2018 | PubMed
  19. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.
    2013 | PubMed
  20. mChIP-KAT-MS, a method to map protein interactions and acetylation sites for lysine acetyltransferases.
    2013 | PubMed
  21. Computational prediction of lysine acetylation proteome-wide.
    2013 | PubMed
  22. Proteome-wide prediction of acetylation substrates.
    2009 | PubMed
  23. Polycomb Group proteins: an evolutionary perspective.
    2007 | PubMed